Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк.filedCriticalЯнссен Байотек, Инк.
Priority claimed from PCT/IB2020/054859external-prioritypatent/WO2020234834A1/en
Publication of EA202193221A1publicationCriticalpatent/EA202193221A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Способ лечения воспалительных заболеваний кишечника, таких как язвенный колит, включает в себя введение ингибитора ИЛ-23, такого как антитело к ИЛ-23р19 (например, гуселкумаб), и ингибитора ФНО-, такого как антитело к ФНО- (например, голимумаб).A method of treating inflammatory bowel disease such as ulcerative colitis comprises administering an IL-23 inhibitor such as an anti-IL-23p19 antibody (eg, guselcumab) and a TNF-α inhibitor such as an anti-TNF-α antibody (eg, golimumab).
EA202193221A2019-09-052020-05-21
METHOD FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASE USING COMBINED THERAPY WITH ANTIBODIES TO IL-23 AND TNF-ALFA
EA202193221A1
(en)